Patents by Inventor Craig R. Woods

Craig R. Woods has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BENZIMIDAZOLES AS MODULATORS OF IL-17
    Publication number: 20250122181
    Abstract: The present application discloses compounds having the following formula (I): or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, and X are defined in the specification, as well as methods of making and using the compounds disclosed herein for treating or ameliorating an IL-17 mediated syndrome, disorder and/or disease.
    Type: Application
    Filed: September 26, 2022
    Publication date: April 17, 2025
    Applicant: Janssen Pharmaceutica NV
    Inventors: Steven D. Goldberg, Douglas C. Behenna, Steven A. Loskot, Stefan J. McCarver, Timothy B. Rhorer, Kristin G. Song, Alexander E. Valdes, Craig R. Woods, Xiahua Xue, Brock T. Shireman, Virginia M. Tanis, Deane Gordan
  • BENZIMIDAZOLES AS MODULATORS OF IL-17
    Publication number: 20240376085
    Abstract: The present application discloses compounds of Formula (I): (I), or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, and R4 are defined in the specification, as well as methods of making and using the compounds disclosed herein for treating or ameliorating an IL-17 mediated syndrome, disorder and/or disease.
    Type: Application
    Filed: September 26, 2022
    Publication date: November 14, 2024
    Applicant: Janssen Pharmaceutica NV
    Inventors: Charlotte Pooley Deckhut, Douglas C. Behenna, Scott Bembenek, Steven D. Goldberg, Paul F. Jackson, John Keith, Steven A. Loskot, Connor Martin, Stefan McCarver, Steven P. Meduna, Timothy B. Rhorer, Amy Y. Shih, Virginia M. Tanis, Craig R. Woods, Xiaohua Xue
  • PHENYL AND PYRIDINYL SUBSTITUTED IMIDAZOLES AS MODULATORS OF RORgT
    Publication number: 20220281823
    Abstract: The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, Ra, Rb, Q1, and Q2 are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-?-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.
    Type: Application
    Filed: May 5, 2022
    Publication date: September 8, 2022
    Applicant: Janssen Pharmaceutica NV
    Inventors: Steven Goldberg, Connor L. Martin, Elizabeth G. Fennema, David A. Kummer, Rachel T. Nishimura, Virginia M. Tanis, Craig R. Woods, Anne M. Fourie, Xiaohua Xue
  • Phenyl and pyridinyl substituted imidazoles as modulators of ROR?T
    Patent number: 11345666
    Abstract: The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, Ra, Rb, Q1, and Q2 are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-?-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.
    Type: Grant
    Filed: June 17, 2019
    Date of Patent: May 31, 2022
    Assignee: Janssen Pharmaceutica NV
    Inventors: Steven Goldberg, Connor L. Martin, Elizabeth G. Fennema, David A. Kummer, Rachel T. Nishimura, Virginia M. Tanis, Craig R. Woods
  • 6-AMINOPYRIDIN-3-YL THIAZOLES AS MODULATORS OF RORyT
    Publication number: 20210221804
    Abstract: The present invention comprises compounds of Formula I. wherein: A1, A2, A3, A4, A5, R1, and R2 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein the syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.
    Type: Application
    Filed: February 23, 2021
    Publication date: July 22, 2021
    Applicant: Janssen Pharmaceutica NV
    Inventors: Steven Goldberg, Kelly McClure, Virginia M. Tanis, Elizabeth G. Fennema, Alec D. Lebsack, Connor L. Martin, Hariharan Venkatesan, Xiaohua Xue, Craig R. Woods
  • 6-AMINOPYRIDIN-3-YL THIAZOLES AS MODULATORS OF RORyT
    Publication number: 20210198251
    Abstract: The present invention comprises compounds of Formula I. wherein: A1, A2, A3, A4, A5, R1, and R2 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein the syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.
    Type: Application
    Filed: February 23, 2021
    Publication date: July 1, 2021
    Applicant: Janssen Pharmaceutica NV
    Inventors: Steven Goldberg, Kelly McClure, Virginia M. Tanis, Elizabeth G. Fennema, Alec D. Lebsack, Connor L. Martin, Hariharan Venkatesan, Xiaohua Xue, Craig R. Woods
  • 6-AMINOPYRIDIN-3-YL THIAZOLES AS MODULATORS OF RORyT
    Publication number: 20210188836
    Abstract: The present invention comprises compounds of Formula I. wherein: A1, A2, A3, A4, A5, R1, and R2 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein the syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.
    Type: Application
    Filed: February 23, 2021
    Publication date: June 24, 2021
    Applicant: Janssen Pharmaceutica NV
    Inventors: Steven Goldberg, Kelly McClure, Virginia M. Tanis, Elizabeth G. Fennema, Alec D. Lebsack, Connor L. Martin, Hariharan Venkatesan, Xiaohua Xue, Craig R. Woods
  • Phenyl substituted pyrazoles as modulators of ROR?t
    Patent number: 10975037
    Abstract: The present invention comprises compounds of Formula I. wherein: R1, R3, R4, R5, R6, R7, R8, and Q are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-?-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.
    Type: Grant
    Filed: June 17, 2019
    Date of Patent: April 13, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Steven Goldberg, Connor L. Martin, Elizabeth G. Fennema, David A. Kummer, Rachel T. Nishimura, Craig R. Woods, Ronald L. Wolin, William M. Jones, Anne M. Fourie, Xiaohua Xue
  • 6-aminopyridin-3-yl thiazoles as modulators of ROR?T
    Patent number: 10975068
    Abstract: The present invention comprises compounds of Formula I. wherein: A1, A2, A3, A4, A5, R1, and R2 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein the syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.
    Type: Grant
    Filed: April 26, 2017
    Date of Patent: April 13, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Steven Goldberg, Kelly McClure, Virginia M. Tanis, Elizabeth G. Fennema, Alec D. Lebsack, Connor L. Martin, Hariharan Venkatesan, Xiaohua Xue, Craig R. Woods
  • Alkyl linked quinolinyl modulators of ROR?t
    Patent number: 10555941
    Abstract: The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.
    Type: Grant
    Filed: March 14, 2016
    Date of Patent: February 11, 2020
    Assignee: Janssen Pharmaceutica NV
    Inventors: Kristi A. Leonard, Kent Barbay, James P. Edwards, Kevin D. Kreutter, David A. Kummer, Umar Maharoof, Rachel Nishimura, Maud Urbanski, Hariharan Venkatesan, Aihua Wang, Ronald L. Wolin, Craig R. Woods, Anne Fourie, Xiaohua Xue, Maxwell D. Cummings
  • PHENYL SUBSTITUTED PYRAZOLES AS MODULATORS OF RORgT
    Publication number: 20190382349
    Abstract: The present invention comprises compounds of Formula I. wherein: R1, R3, R4, R5, R6, R7, R8, and Q are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-?-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.
    Type: Application
    Filed: June 17, 2019
    Publication date: December 19, 2019
    Applicant: Janssen Pharmaceutica NV
    Inventors: Steven Goldberg, Connor L. Martin, Elizabeth G. Fennema, David A. Kummer, Rachel T. Nishimura, Craig R. Woods, Ronald L. Wolin, William M. Jones, Anne M. Fourie, Xiaohua Xue
  • PHENYL AND PYRIDINYL SUBSTITUTED IMIDAZOLES AS MODULATORS OF RORyT
    Publication number: 20190382354
    Abstract: The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, Ra, Rb, Q1, and Q2 are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-?-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.
    Type: Application
    Filed: June 17, 2019
    Publication date: December 19, 2019
    Applicant: Janssen Pharmaceutica NV
    Inventors: Steven Goldberg, Connor L. Martin, Elizabeth G. Fennema, David A. Kummer, Rachel T. Nishimura, Virginia M. Tanis, Craig R. Woods, Anne M. Fourie, Xiaohua Xue
  • Phenyl linked quinolinyl modulators of ROR?t
    Patent number: 10369146
    Abstract: The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.
    Type: Grant
    Filed: June 14, 2016
    Date of Patent: August 6, 2019
    Assignee: Janssen Pharmaceutica NV
    Inventors: Kristi A. Leonard, Kent Barbay, James P. Edwards, Kevin D. Kreutter, David A. Kummer, Umar Maharoof, Rachel Nishimura, Maud Urbanski, Hariharan Venkatesan, Aihua Wang, Ronald L. Wolin, Craig R. Woods, Anne Fourie, Xiaohua Xue, Maxwell D. Cummings
  • Quinolinyl modulators of ROR?t
    Patent number: 10201546
    Abstract: The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.
    Type: Grant
    Filed: March 2, 2017
    Date of Patent: February 12, 2019
    Assignee: Janssen Pharmaceutica NV
    Inventors: Kristi A. Leonard, Kent Barbay, James P. Edwards, Kevin D. Kreutter, David A. Kummer, Umar Maharoof, Rachel Nishimura, Maud Urbanski, Hariharan Venkatesan, Aihua Wang, Ronald L. Wolin, Craig R. Woods, Anne Fourie, Xiaohua Xue, Maxwell D. Cummings, Kelly McClure, Virginia Tanis
  • 6-AMINOPYRIDIN-3-YL THIAZOLES AS MODULATORS OF RORyT
    Publication number: 20170313691
    Abstract: The present invention comprises compounds of Formula I. wherein: A1, A2, A3, A4, A5, R1, and R2 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein the syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.
    Type: Application
    Filed: April 26, 2017
    Publication date: November 2, 2017
    Applicant: Janssen Pharmaceutica NV
    Inventors: Steven Goldberg, Kelly McClure, Virginia M. Tanis, Elizabeth G. Fennema, Alec D. Lebsack, Connor L. Martin, Hariharan Venkatesan, Xiaohua Xue, Craig R. Woods
  • ALKYL LINKED QUINOLINYL MODULATORS OF ROR?t
    Publication number: 20170258782
    Abstract: The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.
    Type: Application
    Filed: March 14, 2016
    Publication date: September 14, 2017
    Inventors: Kristi A. Leonard, Kent Barbay, James P. Edwards, Kevin D. Kreutter, David A. Kummer, Umar Maharoof, Rachel Nishimura, Maud Urbanski, Hariharan Venkatesan, Aihua Wang, Ronald L. Wolin, Craig R. Woods, Anne Fourie, Xiaohua Xue, Maxwell D. Cummings
  • QUINOLINYL MODULATORS OF RORyt
    Publication number: 20170182056
    Abstract: The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.
    Type: Application
    Filed: March 2, 2017
    Publication date: June 29, 2017
    Applicant: Janssen Pharmaceutica NV
    Inventors: Kristi A. Leonard, Kent Barbay, James P. Edwards, Kevin D. Kreutter, David A. Kummer, Umar Maharoof, Rachel Nishimura, Maud Urbanski, Hariharan Venkatesan, Aihua Wang, Ronald L. Wolin, Craig R. Woods, Anne Fourie, Xiaohua Xue, Maxwell D. Cummings, Kelly McClure, Virginia Tanis
  • Quinolinyl modulators of ROR?t
    Patent number: 9624225
    Abstract: The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.
    Type: Grant
    Filed: October 14, 2014
    Date of Patent: April 18, 2017
    Assignee: Janssen Pharmaceutica NV
    Inventors: Kristi A. Leonard, Kent Barbay, James P. Edwards, Kevin D. Kreutter, David A. Kummer, Umar Maharoof, Rachel Nishimura, Maud Urbanski, Hariharan Venkatesan, Aihua Wang, Ronald L. Wolin, Craig R. Woods, Xiaohua Xue, Maxwell D. Cummings, Kelly McClure, Virginia Tanis
  • PHENYL LINKED QUINOLINYL MODULATORS OF RORgammat
    Publication number: 20160279122
    Abstract: The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.
    Type: Application
    Filed: June 14, 2016
    Publication date: September 29, 2016
    Inventors: Kristi A. Leonard, Kent Barbay, James P. Edwards, Kevin D. Kreutter, David A. Kummer, Umar Maharoof, Rachel Nishimura, Maud Urbanski, Hariharan Venkatesan, Aihua Wang, Ronald L. Wolin, Craig R. Woods, Anne Fourie, Xiaohua Xue, Maxwell D. Cummings
  • Phenyl linked quinolinyl modulators of ROR?t
    Patent number: 9403816
    Abstract: The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.
    Type: Grant
    Filed: October 15, 2013
    Date of Patent: August 2, 2016
    Assignee: Janssen Pharmaceutica NV
    Inventors: Kristi A. Leonard, Kent Barbay, James P. Edwards, Kevin D. Kreutter, David A. Kummer, Umar Maharoof, Rachel Nishimura, Maud Urbanski, Hariharan Venkatesan, Aihua Wang, Ronald L. Wolin, Craig R. Woods, Maxwell D. Cummings